[ad_1]
So, if the efficacy of the drug is not all they claim, why do these pharmaceutical companies vigorously promote the drug? Reputation and market share-perhaps the ability to sell other drugs after Covid is under control. “In India, China, and sub-Saharan Africa, the more such drugs, the more Pfizer can sell all the other drugs they want,” Iyer said. “Hospitals can absorb patients with cancer or disease for all the other drugs they produce. From a reputation point of view, it helps a lot.”
To be clear, this does not mean that the drug has no effect. For example, it is likely that 89% of Paxlovid is only shrinking over time.David Bulville, an infectious disease doctor at the University of Minnesota, said: “If these drugs are only used after the emergence of a hospitalized patient, that is, 10 days after the illness, they will not have much impact.” Multiple Covid drug trialsOn the one hand, people must be tested for Covid before they can get a prescription. “That’s complicated. This is difficult (hard. In low-income countries, it is easier for people to get vaccinated. If you can vaccinate high-risk groups, it’s much better than diagnosis and treatment at the same time.”
These two drugs also have complications in actual use. Molnupiravir has been around for 20 years and it targets many different diseases. Mills said that most virologists are desperate to find a real use-partly because researchers have found mutagenicity problems in analyses and experiments over the years. For example, it may not be used for women who are pregnant or may become pregnant.recent article exist statistics Indicates that Merck did not find any problems with the animal test of Monopvir, and statistics Quoting Merck’s executive vice president to tell investors that the company is “confident” in the safety of the drug.
Ritonavir, the second ingredient in Pfizer’s packaging, not only inhibits liver activity; it also has a well-known interaction with anticoagulant drugs and widely used anticholesterol drugs. Therefore, people taking these drugs may have to change the dosage or stop taking them within five days of the entire course of treatment. It is not impossible, but it is also not easy.
Nevertheless, many researchers and public health experts believe that new drugs will help. Even Mills said he thought they would have an impact, although it’s hard to say how big it is. If this model applies to tens of thousands of people, it might be surprising that there were no deaths in the Paxlovid test. “I am very optimistic here,” said Tulio de Oliveira, director of the KwaZulu-Natal Research and Innovation Sequencing Platform at the University of KwaZulu-Natal, South Africa. “The two companies Merck and Pfizer have issued clear guidelines that the prices of medicines provided to developing countries will be much lower. In addition, they have already cooperated with some local companies to produce medicines in developing countries.”
The other side of the large pharmaceutical companies having to prove their huge pre-orders to the government is that these governments are likely to have seen more data than the companies have publicly released. “They had two experiments. They saw data that we didn’t see,” said Eric Topol, director of the Scripps Research and Translational Institute. “They have seen content beyond the press release and, as you can see, they have purchased tens of millions of doses of these two pills.” Topol has been tracking vaccine and drug development work throughout the pandemic, which shows that it is undisclosed The data looks as good as the public data.
[ad_2]
Source link
